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Abstract
Menaquinones have long played a central role in bacterial metabolism due to their
solubility in membranes and their ability to mediate electron transfer reactions between
a large variety of enzymes. In addition to acting as important nodes in fermentation and
respiration,  menaquinones are critical  to the formation of  disulphide bonds in the
periplasm. Their utility as molecular wires has also led to their incorporation into redox
reactions in higher‐order organisms, where they participate in numerous physiological
processes, including blood coagulation. Through studying the menaquinone‐dependent
pathways in organisms across the phylogenetic spectrum, researchers have begun to
uncover intriguing metabolic links and have identified novel compounds for modulating
these vital pathways.
Keywords: menaquinone, vitamin K, vitamin K epoxide reductase, DsbB, disulphide
bond formation
1. Rise of the quinones
As life began to emerge in the seas of primordial Earth, one of the first orders of business was
the construction of a plasma membrane to protect and concentrate biomolecules in the cytoplasm
of what would become the first cell. This served to increase the efficiency of the biochemical
reactions necessary for growth and propagation. The constant influx of salt water across the
plasma membrane, however, would have led to extremely high internal osmotic pressure in
what were essentially bags of chemicals, necessitating the invention of efflux pumps to drive
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ions back out into the surrounding milieu. These early efflux pumps most likely exported protons
at the expense of ATP, which the cells were forced to make through substrate‐level phosphor‐
ylation, an inefficient process. However, leakage of protons back into the cell could drive the
ATPase in the reverse direction, thus linking the extrusion of protons to the creation of cellular
energy.
Aside from the issue of osmotic pressure, the plasma membrane also created a conundrum in
that the organic molecules necessary to drive metabolism were prevented entry. Thus, cells
developed membrane‐associated transporters capable of importing such nutrients. Catabo‐
lism of these organic molecules provided the cells with necessary building blocks and resulted
in the liberation of electrons, which could then be collected on redox‐active molecules like
NAD+ or FAD+, reducing them to NADH and FADH2.
To regenerate the pools of electron carriers, these ancient microbes resorted to fermentation,
the process by which electrons are dropped onto self‐derived organic molecules. This freed up
NAD+ and FAD+ to participate in more rounds of catabolism of carbon sources, thus driving
metabolism. However, fermentation is an inefficient process and thus limited the growth rate
and abundance of these microbes. Only when the enzymes involved in fermentation (i.e.,
nitrate reductase, fumarate reductase) evolved to associate with the plasma membrane did
these ancient microbes begin to tap into the power they needed to flourish. Now, the process
of passing electrons onto terminal acceptors could be coupled to the extrusion of protons into
the extracellular space. With greater numbers of protons pumped out of the cell, their leakage
back across the membrane could greatly increase the amount of ATP generated [1]. In essence,
the cells could target these molecular machines to the membrane to produce the chemical
energy necessary to fuel metabolism. The effect could be further amplified by linking these
redox reactions together, but that required cofactors capable of accepting and donating
electrons to act as molecular wires. The earliest such cofactors were likely iron‐sulfur clusters
and flavins, but these were not readily inserted into the highly lipophilic environment of the
plasma membrane. Thus arose the quinones, which are fat‐soluble redox molecules capable of
associating with membrane‐embedded enzymes. By linking together several modular redox
complexes into an electron transport chain capable of extruding protons, quinones potentiated
a huge leap forward in bioenergetics and greatly increased the capacity for complexity in
biological systems.
To maximize the utility of having quinones available in their membranes, these ancient
microbes needed to find a way to tap into more plentiful electron donors and acceptors. One
potential source of electrons present in abundance on primordial Earth was water. However,
the vast amounts of energy necessary to pull electrons from water presented a formidable
obstacle to its utilization. Only when high‐energy solar radiation came to be employed in the
process known as photosynthesis were “cyanobacteria” successful in linking the fixation of
CO2 to hydrolysis [2]. Quinones were key to the evolution of photosystem I, yet another
example of their power and adaptability in biological systems.
While the increased access to electrons represented a potential windfall to energy‐starved cells,
the development of photosynthesis was nonetheless catastrophic to life on Earth. Concomitant
with the liberation of electrons from water by photosynthesis was the production of a new and
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toxic gas–oxygen. Among the many harmful effects of an oxygenated atmosphere were the
generation of reactive oxygen species, which poisoned the metabolic pathways of early
microbial cells by destroying important cofactors and enzymes [3]. In this noxious environ‐
ment lay opportunity, however, as oxygen could serve as an extremely effective electron
acceptor if cells could evolve mechanisms for reducing it as part of their electron transport
chains. Once again quinones mediated a metabolic breakthrough, linking the reduction of
oxygen to membrane components via cytochrome oxidases. This process of aerobic respiration
led to an estimated 16‐fold increase in the capacity to generate ATP [4] and may have opened
the door to the development of complex eukaryotic life [5].
The metabolic flexibility of quinones means that their use is not limited simply to the respira‐
tory chains of microbes or the photosynthetic centers of plants. Many higher‐order organisms
not only incorporated quinones into their respiratory chains, but have utilized these highly
effective molecular wires in many different redox‐dependent reactions. While the quinones
are ancient, they remain very important to life on this planet.
2. Biosynthesis of menaquinone and phylloquinone
The major quinones found in nature are ubiquinone (UQ), menaquinone (MK), and phyllo‐
quinone (K1) (Figure 1). They differ not only in structure but also in their redox potentials, so
the incorporation of one or the other as a cofactor allows for fine‐tuning of electron transfer
reactions. The distribution in nature of genes involved in menaquinone biosynthesis suggests
that it was most likely the original quinone; this is supported by the observation that mena‐
quinone is readily oxidized in aerobic environments, suggesting that it existed long before the
appearance of oxygen [6]. There are many different species of menaquinone, though they differ
only in the length of their isoprenyl side chains. These differences are reflected in the nomen‐
clature of menaquinones, wherein the number of isoprene units is indicated (i.e., MK‐4).
Phylloquinone, usually considered distinct from the menaquinones, is merely MK‐4 with a
more heavily saturated lipophilic tail.
Figure 1. Structures of common quinones.
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The canonical pathway for menaquinone biosynthesis in bacteria is well‐established and has
been reviewed in great detail elsewhere [7]. Of particular interest to this review, however, is
the prenylation reaction mediated by MenA in which the lipophilic tail is attached to 1,4‐
dihydroxy‐2‐naphthoic acid (Figure 2). In essence, this is the critical step that links the redox‐
active quinone to the membrane. The lipophilic substrate of MenA is made up of repeating
isoprenal subunits, the exact number of which is determined by the octaprenyl pyrophosphate
(OPP) synthase encoded by the particular microbe. The ultimate chain length of these products
is determined by a molecular ruler mechanism wherein bulky amino acid residues at the
bottom of each of OPP's active sites block chain elongation [8], and it is this step that controls
the identity of the primary MK produced by an organism. There is some evidence to suggest,
however, that growth temperature also plays a role in the length and degree of saturation of
the aliphatic side chain [9]. Phylloquinone biosynthesis in cyanobacteria is predicted to
proceed via a pathway very similar to that of MK biosynthesis. However, the cyanobacterial
MenA incorporates a mostly saturated phytyl tail at position C‐3 rather than the partially
unsaturated isoprenyl side chain associated with MK [10]. Recently, an alternative pathway
Figure 2. Biosynthesis of menaquinone and phylloquinone. The highly conserved sequence of reactions required for
conversion of chorismate to menaquinone is shown. The pathway for phylloquinone biosynthesis is thought to pro‐
ceed via the same steps, with the exception of the prenylation step mediated by MenA. The production of demethyl‐
phylloquinone versus demethylmenaquinone is determined by which substrate is provided to MenA by octaprenyl
pyrophosphate synthase (OPP). A phytyl chain results in the production of demethylphylloquinone, whereas a more
highly unsaturated isoprenyl chain results in demethylmenaquinone. In mice, metabolism of phylloquinone in the liv‐
er has been shown to release menadione, which in turn can be prenylated by the MenA homolog UBIAD1 to produce
menaquinone.
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for menaquinone biosynthesis has been described in several Achaea and Gram‐negative
bacteria, including Helicobacter pylori, Chlamydia species, and spirochetes [11]. While both
pathways start with chorismate, the formation of the quinone proceeds via completely
different reactions. The diversity of pathways for biosynthesis of MKs serves to underscore the
importance of its role in metabolism.
Phylloquinone biosynthesis in plants is not as well understood as in cyanobacteria, though the
pathway likely mirrors that of menaquinone. One striking difference is that the first four
reactions proceeding from chorismate, mediated by the products of the menF, D, C, and H
genes in bacteria, are accomplished in plants by one fusion protein known as PHYLLO [12].
Later steps are compartmentalized between the chloroplast and peroxisome, adding an
additional level of complexity to production in plants [13].
Unlike the organisms mentioned above, higher‐order organisms are incapable of de novo
synthesis of MKs. It is therefore imperative that MKs be supplied through diet, thus classifying
MKs as a “vitamin” for mammals. The identification of MKs as essential vitamins arose from
the Nobel Prize‐winning work of Edward Adelbert Doisy and Henrik Dam in 1943. Their
recognition that a fat‐soluble compound played a key role in blood coagulation led them to
name it “vitamin K” (“K” for the German word “Koagulationsvitamin”). Purification and
characterization revealed two forms of vitamin K—phylloquinone thus became known as
vitamin K1 and menaquinone as vitamin K2 with regards to their requirement in mammals.
Though humans cannot synthesize vitamin K de novo, several homologs of menaquinone
biosynthetic enzymes can be found in the human genome, including one for the prenylating
enzyme MenA (UBIAD1). This enzyme was expressed in an insect cell line and was shown to
be capable of converting menadione (K3) and K1 into MK‐4 [14]. Such a result suggested that
while humans cannot make their own MKs, they may be capable of converting biosynthetic
intermediates into the final product. Indeed, recent results show that the phytyl tail of K1 is
cleaved in the intestine of mice to make K3 and then prenylated by UBIAD1 in the cerebrum
[15, 16]. Furthermore, human subjects fed K1 exhibited increased levels of K3, indicating that
dietary K1 may play a major role in overall MK levels [16], and gnotobiotic rats fed K1 saw
increased levels of MK4 in tissues, indicating that the conversion is not dependent on gut
bacteria [17]. UBIAD1 has also been demonstrated to be essential for the embryonic develop‐
ment of mice [18], so vitamin K's route through the body is not completely understood and
the complexities begin with the vitamin's source.
3. Sources of vitamin K
While the reactions requiring vitamin K in human metabolism are becoming clearer, the source
of the vitamin K is still not completely understood. The presence of large numbers of bacteria
in the human colon capable of synthesizing K2 would perhaps suggest that absorption of this
bacterial byproduct might fulfill the human requirement. In fact, MK‐6 is made by Eubacterium
lentum, MK‐7 by Veillonella, MK‐8 by Enterobacteria, and MK‐10 and MK‐11 are made by
Bacteroides [19, 20]. The bacterial contribution to vitamin K pools in humans is supported by
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studies done with gnotobiotic rats fed vitamin K‐free diets. The rapidly developing hemor‐
rhagic conditions in these rats could be reversed by supplying bacteria from conventionally
raised rats, suggesting that absorption from the bowel provided sufficient quantities of K2 [21].
Concordant with this is the observation that taking broad‐spectrum antibiotics can reduce
vitamin K production by more than 70% [22]. However, K2 is embedded within the bacterial
inner membrane, and as such would appear to be inaccessible to passive absorption. MKs have
been shown to be secreted by some organisms [23], and it is also possible that water‐soluble
precursors of MK biosynthesis might be more readily available [7]. However, this scenario is
further complicated by the fact that there is very little evidence that the large intestine is capable
of absorption of MKs. Uptake has been shown to be poor in rats [24] and infants [25]. Even the
finding that antibiotic treatment lowered vitamin K production does not conclusively identify
bacteria as a major source of human vitamin K2 pools, as some antibiotics have been shown
to inhibit the human enzymes necessary for recycling vitamin K2 [26]. The role of the micro‐
biome in the production of K2 is therefore questionable and would suggest that perhaps
vitamin K stores in humans might be the result of dietary intake.
Low concentrations of vitamin K2 can be found in dairy, meat, and fermented foods like natto
[27], but makes up only 10% of total dietary vitamin K intake. While K1, found in a variety of
green leafy plants and vegetable oils, is present in much higher amounts, it is not readily
absorbed in the intestines as it is strongly bound to vegetable fiber [28]. Vitamin K is not
transported by specific plasma carrier proteins like other fat‐soluble vitamins, but is instead
shuttled by lipoproteins. The small fraction of K1 that is absorbed is almost exclusively
incorporated into the triacylglycerol‐rich lipoprotein (TGRLP) fraction, while dietary K2 is
associated with low‐density lipoprotein (LDL) fraction [29]. These divergent pathways would
deliver large amounts of K1 to the liver, but efficient delivery to extrahepatic tissues would
only occur for K2. Measurements of the concentrations of vitamins K in various tissues mostly
back this up, showing that K1 levels are low in the brain, kidneys, and lungs but high in the
liver, heart, and pancreas; K2 (in the form of MK‐4) was found to be in high concentration in
the brain, kidneys, and pancreas but in low concentration in the liver, heart, and lungs. As for
longer chain K2s, MK6‐11 were found in the liver and trace amounts of MK6‐9 were found in
the heart and pancreas [30]. MK10 and MK11 may be major contributors to the hepatic pool
of K2 [26], and the presence of these long‐chain MKs again raise the possibility that the
commensal population of colonic bacteria may somehow contribute to overall vitamin K levels
in the host, as analysis of tissue samples has only shown the ability to synthesize MK‐4 from
K1. However, the presence of potential homologs for other prenyl diphosphate synthases in
the genome further suggests that humans may be capable of producing longer chain MKs as
well. Overall the data clearly indicate that dietary K1 is a major contributor to vitamin K levels
in the body, but a full accounting of its sources has yet to emerge.
4. Uses of vitamin K
While the side chains of K1 and the various MKs differ, the redox‐active portion of the
molecules (the napthoquinone) remains unchanged. The reactivity of these various species
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should therefore be very similar, a fact underlined by the nearly identical mid‐point redox
potentials as determined by voltammetry [31, 32] (Figure 3). The degree of lipophilicity in the
tails most likely dictates mobility of the quinones in the membrane, with the partially saturated
isoprenyl tail of MK allowing for greater freedom of movement compared to the mostly
unsaturated chain of K1. Additionally, longer chain MKs are likely stiffer and more viscous in
the membrane due to the greater surface areas available for van der Waals interactions. For
these reasons, the preferential incorporation of one MK over another into a redox‐active
enzyme is most likely due to availability within the membrane as well as the ability of the
enzyme to accommodate different length side chains. In microsomal fractions, MK2 and MK3
were shown to have much higher activities than K1 [33], while a partially purified enzymatic
system showed similar activities for MK2‐6 compared to K1. MKs with seven or more isopre‐
noid units were not as active [34].
Figure 3. Resonance structures of napthoquinone species. Two electrons (e‐) can be accepted or donated in step‐wise
transfers from partner proteins.
Vitamin K2 has been found to play a role in protection against oxidative stress and inflamma‐
tion in mammals [35], and improved locomotion defects in mutant fruit flies [36], suggesting
that it might benefit human patients suffering mitochondrial pathologies. Mounting evidence
suggests that MK‐4 is an important component of sphingolipid biosynthesis and can inhibit
the proliferation of several cancer cell lines [37]. The exact role of vitamin K2 in these processes
is unknown however—its most thoroughly understood use is in protein modification.
Numerous proteins in vertebrates are modified post‐translationally as a means of regulating
and enhancing their activity. One such modification is the carboxylation of glutamate residues
within Gla domains, which is mediated by the enzyme gamma‐glutamyl carboxylase (GGCX).
This modification allows for the high‐affinity binding of calcium ions, which in turn mediates
a conformational change necessary for proper folding of the protein. Gla‐containing proteins
play important roles in the venom of snakes and the toxins of cone snails [38], and they have
numerous functions in humans including bone development, calcification, and sphingolipid
metabolism [35, 39]. The cell‐signaling activities of the vitamin K‐dependent proteins Gas6 and
protein S may also be crucial to cognitive processes [35]. Among the Gla‐containing proteins,
however, those involved in blood coagulation have received the most attention. Carboxylation
of several of these factors activates them and thereby sets off a cascade leading to clotting. The
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GGCX glycosylation reaction is coupled to the oxidation of vitamin K hydroquinone to vitamin
K 2,3‐epoxide, and it is this step that shows sensitivity to anticoagulants like warfarin. When
this vitamin K cycle is disrupted or insufficient quantities of vitamin K are present in the diet,
excessive bleeding can and does occur, as was the case in the initial discovery of vitamin K's
role in nutrition.
While the flexibility of K2s is crucial to all of these redox‐driven processes, short circuits occur
wherein reduced menaquinones donate their electrons to “inappropriate” acceptors like
oxygen. Such reactions result in the production of reactive oxygen species and can lead to
massive damage to proteins and DNA [40, 41], underlining the importance of properly
regulating the expression and distribution of MKs.
5. VKORs
Clearly, MKs play a critical role in mediating the activity of numerous proteins in mammals,
yet the levels of this important cofactor in tissues is relatively low. After passing electrons onto
the appropriate acceptors, MK is oxidized to its inactive, oxidized form. In bacteria, MK is
quickly reduced again by the flow of electrons from the electron transport chain or to a lesser
extent by the delivery of electrons from the disulfide bond pathway. To recharge and replenish
their redox‐active pool of MKs, mammals have evolved enzymes capable of reducing of
vitamin K 2,3‐epoxide (KO) to vitamin K and vitamin K hydroquinone (KH2). These two steps
occur via a warfarin‐sensitive pathway as well as a warfarin‐insensitive pathway, suggesting
that two or more enzymes may be required to efficiently complete the reaction. While the
enzymatic activity of vitamin K epoxide reductase (VKOR) had first been assayed in 1974 and
VKOR had long been known to be the target of the anticoagulant warfarin, identification of
the enzyme responsible for the regeneration of vitamin K did not come until 2004 [42, 43].
While this discovery set the stage for in‐depth analysis of the kinetics of blood coagulation,
one of the most surprising early findings was that VKOR homologs could be found not only
in a large family of vertebrates, but also in insects, plants, bacteria, and archaea [44]. What role
could VKOR possibly play in organisms that do not contain blood? The discovery of vitamin
K‐dependent proteins in sea squirts [45] suggests that this modification arose much earlier
than the blood coagulation cascade and that vertebrates simply repurposed Gla‐modified
proteins.
To fully understand the function of a membrane‐bound protein, it is important to determine
the topology of the enzyme within the membrane. This allows for greater insights into the
catalytic site as well as to possible interactions with partner proteins. The topology of VKOR
in the endoplasmic reticulum (ER) membrane, however, has been fraught with controversy.
Initial reports suggested an enzyme with 4 transmembrane domains (TM) [44], though there
is also mounting evidence that VKOR may adopt a 3‐TM structure (Figure 4). Of particular,
importance to this debate is the potential positioning of critical cysteine residues. VKOR
contains a total of four conserved cysteines, two of which are present in a C‐X‐X‐C motif
characteristic of redox‐active thioredoxins. These two cysteines (C132 and C135) have been
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shown to be essential for the reduction of vitamin KO to vitamin K and vitamin KH2 using
purified VKOR [46]. The second set of conserved cysteines (C43 and C51) lie within a loop
region between TMs. The 3‐TM model for VKOR places the N‐terminus of the protein and the
active site cysteines on the ER side of the membrane, with the loop cysteines and C‐terminus
in the cytoplasm. On the other hand, the 4‐TM model places both termini in the cytoplasm,
while the active site and loop cysteines both face the ER lumen. This 4‐TM topology would
immediately suggest an enzymatic mechanism wherein the loop cysteines receive electrons
from interactions with redox partners in the lumen, and then pass them on to the active site
C‐X‐X‐C. Because the 3 ‐TM model predicts that the two sets of cysteines are on opposite sides
of the ER membrane, it is difficult to imagine how they might interact, and it suggests a
distinctly different mechanism for reduction. The fact that several mutations encoding
Figure 4. Representative topologies of membrane redox proteins. (A) Topologies of DsbB and Mtb VKOR in the bacteri‐
al plasma membrane. Critical cysteine resides required for transfer of electrons to menaquinone are represented by yel‐
low circles, while loop cysteines required for accepting electrons from the periplasmic protein DsbA are represented as
gray circles. Note that the order of these residues is reversed in the two enzymes with respect to the amino acid se‐
quences. (B) Proposed topologies of the mammalian VKOR in the membrane of the endoplasmic reticulum. In the 3‐
TM structure, the loop cysteines and those required for transfer of electrons to menaquinone (vitamin K2) are located
in different cellular compartments, while in the 4‐TM model, all four are found near the interface of the membrane
with the ER lumen. While several luminal proteins have been found to be capable of transferring electrons to the cata‐
lytic site of VKOR in the 4‐TM model, it is not yet clear which proteins would perform this role in the 3‐TM model.
MK = menaquinone. GGCX = γ‐glutamate carboxylase.
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resistance to warfarin map to the loop region containing Cys43 and Cys51 further suggests
that these loop cysteines may play a key role in VKOR activity.
The loop cysteines were not required for the enzymatic of activity of VKOR with the purified
enzyme, though C51 was found to be important along with C132 and C135 for activity in cell
extracts [47]. Expression of Cys 43 and Cys 51 mutants in reporter cells in which endogenous
VKOR and VKORL1 were knocked out show that these mutant alleles retain ∼90% activity
[48]. However, challenges to such results have emerged. Results with purified VKOR showing
the non‐essentiality of the loop cysteines were obtained using dithiothreitol (DTT), a non‐
physiological reductant. Because DTT is membrane permeable, it is possible that Cys43 and
Cys51 are important for shuttling electrons to the active site cysteines under physiological
conditions, but DTT bypasses this necessity. To this end, experiments utilizing the membrane
impermeable system of NADPH, thioredoxin, and thioredoxin to drive reduction gave results
showing that the loop cysteines were actually required for VKOR activity [49].
The membrane topology of VKOR has been directly tested through a number of biochemical
approaches. The Stafford lab fused green fluorescent protein (gfp) to either the N‐ or C‐
terminus and tested protease susceptibility. These studies showed that only the C‐terminus
was proteolytically cleaved, which suggested that while the N‐terminus faced the ER lumen,
the C‐terminus must face the cytoplasm. This architecture placed the two confirmed active site
cysteines (Cys‐132 and Cys‐135) on the luminal side of the membrane, while the two conserved
loop cysteines (Cys‐43 and Cys‐51) were on the opposite side [50]. An important caveat to this
work is that the protease sensitivity assay was performed after permeabilization with digito‐
nin, a process not thought to affect the topology of membrane proteins. However, a very similar
approach using live (i.e., non‐permeabilized) cells and a redox‐active gfp clearly demonstrated
that both the N‐ and C‐termini are located within the cytoplasm [51]. Further experiments
showed that the loop region containing Cys43 and Cys51 could be glycosylated by machinery
within the ER lumen and that the loop cysteines could form mixed disulfides with luminal
proteins, thereby placing this loop region firmly in the ER in accordance with a 4‐TM topology.
The overall architecture of VKOR becomes most germane when attempting to identify its redox
partners. If VKOR had three membrane‐spanning domains, the loop cysteines would not be
accessible to soluble redox partners, yet the active site cysteines would need to be directly
accessible to a partner. To achieve this, the partner must also be membrane bound, as has been
suggested for GGCX [52], or must have a hydrophobic domain capable of inserting into the
membrane during electron transfer. A potential membrane complex of VKOR and GGCX
would explain how a transfer reaction between these two enzymes could be facilitated during
blood coagulation, but it does not offer any insights into how electrons might be supplied to
VKOR in the first place. Despite the fact that molecular dynamic simulations indicate that the
3‐TM model of human VKOR has a structural advantage in terms of protein stability over a
VKOR with 4 TM [53], questions regarding this model still remain.
In a 4 TM structure of VKOR, the active site cysteines face the ER lumen. It has therefore been
hypothesized that VKOR's redox partner must be a luminal protein that most likely bears at
least some homology to thioredoxin‐like proteins, which encode cysteines in a C‐X‐X‐C motif.
The proposed reaction scheme posits that Cys‐43 of VKOR forms a mixed disulfide with its
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redox partner, which subsequently attacks Cys‐51 to form an intramolecular disulfide bond in
VKOR and releases the redox partner. By mutating the resolving Cys‐51, the mixed disulfide
can be trapped, thus allowing identification of the redox partner. Such an approach identified
several intriguing candidates including soluble proteins and the membrane‐bound TMX,
TMX4, and ERp18 as forming mixed disulfides with VKOR, although it is not clear what the
downstream effects of such interactions might be [54].
Early studies with microsomal fractions indicated that protein disulfide isomerase (PDI) might
be an important source of electrons for VKOR [55], which is consistent with PDI's localization
to the ER lumen. PDI can act as an electron acceptor by interacting with proteins containing
multiple cysteine residues. By accepting electrons from such proteins, disulfide bonds form
between these cysteines, which can serve to stabilize or activate these substrates. Following
this reaction, the reduced form of PDI is free to donate its electrons to other partner proteins.
Studies confirmed that PDI could stimulate VKOR's reductive activity and went on to suggest
that VKOR and PDI may even form a complex in the ER membrane [56]. In other words, the
reduction of vitamin KO may be driven by the formation of disulfide bonds in the ER lumen.
Such a mechanism appears to contribute to the overall redox homeostasis within the ER [57]
and has also been suggested to operate in plants as well [58, 59].
While VKORs can be found in numerous classes of organisms, paralogs of VKOR are also quite
prevalent. Known as “VKORLs” (“VKOR‐like”), the exact role of these enzymes is still unclear.
The human VKOR and VKORL1 share 42% identity and 60% similarity. Like VKOR itself,
VKORL1 can reduce KO to vitamin K, which may explain why patients treated with anticoa‐
gulants do not exhibit significant side effects that would be expected from the inability to turn
over vitamin K, like arterial calcifications [60]. Indeed, rat VKORL1 was shown to be up to 50‐
fold more resistant to warfarin as compared to VKORC1 in one study [61], although such a
finding has been contested [62]. However, the rate at which VKORL1 reduces KO may be
significantly slower than VKOR [60], and mice missing VKOR (but expressing VKORL1) bled
to death shortly after birth [63], suggesting a different function for VKORL1. It has also been
suggested that VKORL1 may play a role in the vitamin K cycle by reducing vitamin K to KH2
[64], although such a suggestion may be premature, as comparisons of VKOR and VKORL1
activity can be problematic [62]. To gain further insight into the differential functions of
VKORL1 versus VKOR, these authors looked at expression levels of the two genes in different
tissues. They found clear evidence that VKOR and VKORL1 are differentially regulated in rats
and mice, with VKOR showing higher expression in rat liver, lung, and kidney, VKORL1
showing higher expression in the brain, and similar expression profiles in the testis. Overall,
the levels of VKORL1 were relatively constant across organs, while VKOR showed extremely
high levels in the liver but much lower levels in the remaining tissues [61]. Such findings have
led some to hypothesize that VKOR may have evolved to provide cofactor to the vitamin K‐
dependent proteins required for maintaining the high‐flux environment of the circulatory
system and the homeostasis of a calcified skeleton, while the ability of VKORL1 to reduce
vitamin K may be ancillary to its role in antioxidant functions and disulfide bond formation
[39]. The differential activity of VKORL1 compared to VKOR is supported by studies conclu‐
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sively showing that the loop cysteines of VKORL1 are required for activity, in potential contrast
to VKOR [62].
The quest to define a role for bacterial VKORs began with an observation that arose from
studies of a well‐defined, quinone‐dependent pathway in bacteria responsible for catalyz‐
ing the formation of disulfide bonds in some periplasmic proteins. As covalent bonds be‐
tween cysteine residues, disulfide bonds can stabilize otherwise energetically unfavorable
conformations of certain proteins, thus promoting functionality, similar to binding of calci‐
um ions in the Gla‐dependent proteins of eukaryotes. While most disulfide bonds in the
bacterial cytoplasm exist transiently as part of an enzyme catalytic cycle, disulfide bonds in
the periplasm are much more stable. This is due to the activity of disulfide‐bonding protein
A (DsbA), which utilizes two cysteine residues to accept electrons from substrate proteins
[65, 66]. Such an electron‐transfer reaction leads to the oxidation of the substrate protein
(disulfide‐bonded), while leaving the cysteine residues of DsbA in the reduced form (‐SH).
To regenerate active DsbA, electrons need to be transferred to another protein, DsbB [67,
68]. DsbB is localized to the plasma membrane via four transmembrane‐spanning domains
and utilizes two pairs of active‐site cysteines to accept electrons from DsbA and pass them
onto ubiquinone or menaquinone [69–71]. These quinone carriers deposit the electrons onto
a final electron acceptor like oxygen or nitrate through the process of respiration, thus com‐
pleting the disulfide bond generation cycle. While homologs of DsbA and DsbB have been
identified in many bacteria, some do not encode these enzymes but contain disulfide‐bond‐
ed proteins [72]. To identify the enzymes responsible for generating disulfide bonds in
these organisms lacking DsbB, bioinformatics analysis was performed. The results of this
analysis demonstrated that some bacteria encoded a DsbA‐like protein fused to a homolog
of eukaryotic VKOR [44, 72]. Because VKOR and DsbB both utilize catalytic cysteine resi‐
dues in redox‐dependent transfer reactions, have multiple membrane‐spanning domains,
and are known to reduce quinones, it suggested that the bacterial VKOR might function in
a manner analogous to DsbB. Concordant with this, VKOR homologs were found only in
bacteria‐ and archaea‐lacking DsbB [72]. In fact, the VKOR encoded by Mycobacterium tu‐
berculosis (Mtb) can restore disulfide bond activity to an E. coli strain missing dsbB [72], and
a VKOR homologue has been shown to catalyze disulfide bond formation in cyanobacteria
[73]. Therefore, despite the fact that DsbB and VKOR show no significant homology at the
amino acid level, they perform analogous reactions. Perhaps even more striking, the
VKOR‐dependent disulfide bond activity in this E. coli strain can be inhibited by high con‐
centrations of the anti‐coagulant warfarin, providing another link between the bacterial
and eukaryotic enzymes [74]. Such results are of course strikingly analogous to the poten‐
tial role of VKORL1 in the formation of disulfide bonds in the ER lumen. The crystal struc‐
ture of the fused DsbA‐VKOR from Synechococcus suggests that the reactions performed by
bacterial and eukaryotic VKORs may proceed via similar mechanisms and may provide
insights into the inhibition by warfarin and other anti‐coagulants [75, 76]. The Synechococ‐
cus VKOR (synVKOR) is, however, slightly different than the mammalian enzyme in that it
utilizes ubiquinone as a cofactor rather than MK. The epoxide form of ubiquinone has not
been found in Synechococcus, as with other bacteria, and synVKOR cannot reduce vitamin
KO to the hydroquinone form [75]. While DsbB has been shown to encode four transmem‐
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brane domains, studies using fusion proteins show that the bacterial VKOR spans the plas‐
ma membrane five times, with the fifth‐TM segment usually allowing for the fusion to the
periplasmic DsbA. Despite this difference in topology, all four active site cysteines face the
periplasm [77]. Like DsbB, the cysteines in bacterial VKOR are essential for the formation
of a mixed disulfide with DsbA, but the pairs of cysteines are reversed in regards to their
order within the amino acid sequence [77]. Phylogenetic analysis of VKOR and DsbB sug‐
gests that these two enzymes are in fact related evolutionarily, having diverged from a sin‐
gle lipidic quinone–disulfide oxidoreductase superfamily [78]. The diversion would appear
to have led to differential function as well, for while eukaryotic VKORs reduce the epoxide
form of K2 to the quinone and the hydroquinone form in order to provide substrate for the
gamma‐glutamate carboxylase reaction, there is no evidence for gamma‐glutamate carbox‐
ylases in bacteria.
Despite the fact that there is little overall homology in the amino acid sequences of human
VKOR and Mtb VKOR, the enzymes appear to catalyze very similar reactions, at least from a
redox perspective. It is therefore interesting to test whether they are interchangeable. Expres‐
sion of Mtb VKOR in mammalian cell lines confirmed that the bacterial VKOR is capable of
reducing both vitamin K and vitamin KO to KH2 [79]. While the loop cysteines of Mtb VKOR
(Cys‐57 and Cys‐65) are essential for disulfide bond activity when expressed in E. coli, they
may not be required for reduction of vitamin K epoxide in mammalian cells [79].
Studies of the functionality of mammalian VKORs in bacteria have been more problematic.
Expression of hVKOR in E. coli results in the formation of inclusion bodies, thus preventing
any attempts to assess function in vivo. Additionally, reconstitution of recombinant hVKOR
activity from insoluble fractions was strictly dependent on the nature of the membrane
composition [80]. Attempts to restore disulfide bond formation to a ΔdsbB strain of E. coli by
expressing either the rat or human VKOR have so far been unsuccessful at least in part due to
the lack of stable expression [81]. However, selection for a rat VKOR functional in substituting
for DsbB in this system yielded a collection of mutants in the rat vkor gene that encoded amino
acid changes in the protein. Notably, many of these gain of function mutations resulted in
changes in the charge of what is predicted to be the first periplasmic loop of rat VKOR when
it is expressed in E. coli. The charge distribution of amino acids is known to play an important
role in establishing the proper topology of membrane proteins [82, 83]. Further, even higher
levels of protein are detected when the mutant proteins are expressed in E. coli strains carrying
mutations that alter the YidC insertase, a protein necessary for membrane localization of some
proteins or mutations eliminating the cytoplasmic protease HslV [81]. Mutant strains harbor‐
ing both yidC and hslV mutations showed significantly more VKOR activity and protein levels.
These results suggest that while the bacterial VKOR can be properly inserted into the ER
membrane for the reduction of vitamin KO, the mammalian VKOR may not be able to be
properly inserted in the bacterial plasma membrane without initial changes in the protein itself.
Nevertheless, the mutant versions of rat VKOR that are expressed in E. coli are sensitive to
anticoagulants, suggesting that the functional expression even of the mutant enzyme may
provide a powerful tool for its study.
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6. Vitamin K2 as a target for inhibition
MKs are clearly critical components of many aspects of the growth and proliferation of
bacterial and human cells, but most of the enzymes necessary for their biosynthesis are only
bacterially encoded and are missing from humans. MK biosynthesis would appear to be an
ideal target for the development of small molecule inhibitors as potent antibiotics. Among
pathogenic bacteria, Mtb poses one of the most significant threats, as it accounts for nearly two
million deaths annually. While combinatorial antibiotic therapies have been developed against
Mtb, serious complications have arisen that compromise the efficacy of these treatments. In
addition to excessive length of treatment, the side effects of these drugs can be debilitating,
and antibiotic resistance has arisen at a startling rate. In addition, Mtb can remain for long
periods of time in a dormant state in which traditional antibiotics are not effective. However,
even in this quiescent state, Mtb requires an active electron transport chain to maintain
adequate levels of ATP, and MKs therefore play a key role [84]. To this end, researchers have
developed screens specifically targeting the MK biosynthetic pathway of Mtb. Early results
show that compounds‐targeting MenE show some promise [85], and the prenylating enzyme
MenA is also being developed as a target [86, 87]. Most strikingly, one MenA inhibitor
(allylaminomethanone‐A) was shown to be up to 320‐times more effective in killing non‐
replicating Mtb than first line drugs currently prescribed for infection [84], and MenA inhibi‐
tors have been shown to inhibit growth of Mtb resistant to commonly used antitubercular
drugs [86]. Caution must be exercised in advancing such therapies, however, as the full scope
of vitamin K metabolism in the body has not been elucidated. If gut bacteria do contribute
significantly to vitamin K stores in the body, then inhibitors targeting MK biosynthesis may
have significant effects on blood coagulation and bone calcification, for example. MenA
inhibitors are particularly noteworthy, since off‐target effects on the human homolog UBIAD1
could potentially disrupt a number of cellular processes that are only beginning to be under‐
stood.
As an inhibitor of vitamin K‐dependent reactions, warfarin has long been used as an anticoa‐
gulant that at least in part targets human VKOR. While the mycobacterial VKOR has been
shown to be sensitive to warfarin, the amount necessary to inhibit the bacterial enzyme is
orders of magnitudes higher than the amount needed to prevent blood coagulation [74]. This
would suggest that while the human and bacterial VKORs can perform similar functions and
do so by similar mechanisms, the divergence in the amino acid sequence of the two is significant
enough that treatment of mycobacterial infection with anticoagulants would not be an effective
therapeutic strategy. However, ferulenol, an anticoagulant, shown to be approximately 20‐fold
more potent against human VKOR than warfarin, showed similar potency against the
VKOR from Synechococcus [75]. It is therefore possible that drug discovery efforts to identify
novel anticoagulants may impact the search for inhibitors of bacterial VKOR and vice versa.
Disulfide bond formation appears to be dispensable for in vitro aerobic growth of E. coli and
other bacteria, although many virulence factors absolutely require disulfide bonds for proper
assembly and function. Bacteria disrupted in the DSB pathway are rendered less virulent, and
E. coli cannot grow anaerobically, suggesting that small molecule inhibitors of DsbB‐ or VKOR‐
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dependent pathways may be potent anti‐virulents and may prevent anaerobic growth of some
pathogens. Mtb is especially vulnerable to such compounds, as VKOR is essential for growth
of this organism, even in aerobic environments [88]. Bacterial DsbBs and VKORs therefore
make attractive targets for antibiotic therapies.
The fact that DsbB and MtbVKOR perform complementary functions but lack amino acid
homology allowed our laboratory to develop a screen to identify potential small molecule
inhibitors that specifically target DsbB or MtbVKOR [89]. β‐galactosidase (LacZ) is a cytoplas‐
mic enzyme capable of cleaving the disaccharide lactose to yield galactose and glucose. The
activity of this enzyme can be readily monitored in E. coli by using the lactose analog Isopropyl
5‐bromo‐4‐chloro‐3‐indolyl‐β‐D‐galactopyranoside (X‐gal)—successful cleavage of X‐gal
yields an insoluble blue dye that can readily be distinguished by eye. When lacZ is fused to
the gene encoding the membrane protein MalF, however, the enzyme is exported into the
periplasm and is inactivated by the formation of inappropriate disulfide bonds. Strains
expressing this fusion construct appear white on X‐gal, as the substrate cannot be cleaved.
However, strains lacking dsbB appear blue on X‐gal when expressing this construct, as these
cells lack the ability to catalyze the formation of the inappropriate disulfide bonds in LacZ. In
such a case, LacZ is active and capable of cleaving X‐gal. When the ΔdsbB strain is comple‐
mented with a construct expressing lowered‐levels of dsbB or with Mtb vkor, the strains appear
white again, as disulfide bond formation is restored. When libraries of small molecules are
applied to E. coli strains differentially expressing E. coli dsbB (or the dsbB from another Gram‐
negative bacterium) or Mtb vkor along with the MalF‐LacZ fusion in a high‐throughput format,
specific inhibitors of DsbB or VKOR can easily be identified by the appearance of a blue color.
The differences in the primary structure of DsbB and VKOR would suggest that any compound
that inhibits one should not inhibit the other. For this reason, each strain acts as a strong counter
screen for the other. We have successfully employed this screen to identify several strong,
specific inhibitors of the DsbB from E. coli as well as several other important pathogens, and
we continue to use it to screen for potential inhibitors of the Mtb vkor. Further efforts to express
functional mammalian VKOR and VKORL1s in the E. coli screening strain would not only
provide a means by which to test potential side effects of compounds targeting the bacterial
enzymes, but may offer a high‐throughput approach to identifying new compounds capable
of inhibiting VKOR‐dependent processes in mammals. Additionally, because the screening
system provides an easily monitored readout for VKOR activity, it might be used to study
hVKOR variants shown to be resistant to anticoagulant therapies. Such studies could lead to
more precisely targeted and potent blood thinners.
7. Conclusions
Since their incorporation into the electron transfer pathways of ancient microbes, menaqui‐
nones have become a cornerstone of redox‐dependent reactions in almost every domain of life.
Their ability to interact with a large variety of proteins, to readily accept and donate electrons,
and to easily move within biological membranes have combined to make MKs flexible and
efficient molecular wires. As such, organisms have evolved to integrate MKs into many
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metabolic processes, thus plugging into previously untapped sources of power. While
researchers have seemed to only scratch the surface of the myriad uses for MKs to this point,
further investigation will yield not only fascinating insights into the biochemical pathways
critical to life, but may be a crucial starting point for the development of therapies designed
to protect and enhance those pathways.
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